May 21, 2026DiagnosticsOpen Access

Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications

View Full Paper

Ask AI

Bookmark

Why the study?

Does FAPI PET improve imaging of oncologic and fibroinflammatory diseases compared to [18F]FDG?

Population

256 sources reporting on FAPI-targeted PET in human subjects or translational models with oncologic and…

Comparison

[68Ga]- and [18F]-labeled fibroblast activation… vs [18F]FDG PET

Design

Systematic_review

Authors

EPEmmanouil Panagiotidis FKFilippos Koinis JZJules Zhang-Yin

Discussion

Member takes

Implication

FAPI PET may enhance fibrosis imaging in oncologic and fibroinflammatory diseases; leaves open prospective cardiovascular validation before clinical adoption.

Structured PICO

Does FAPI PET improve imaging of oncologic and fibroinflammatory diseases compared to [18F]FDG?

Population

256 sources (original studies, systematic reviews, meta-analyses, clinical guidelines, case series, and case reports) reporting on FAPI-targeted PET in human subjects or translational models with oncologic and fibroinflammatory diseases.

Intervention

[68Ga]- and [18F]-labeled fibroblast activation protein inhibitor (FAPI) tracers for positron emission tomography (PET) imaging

Comparator

[18F]FDG PET

Outcome

Diagnostic utility, lesion conspicuity, and translational potential of FAPI PET in oncologic and fibroinflammatory diseasessurrogate

FAPI PET is an emerging molecular imaging platform with strong translational potential for targeting activated fibroblasts in oncology and fibroinflammatory diseases, including cardiac fibrosis.

Limitations

Lack of large-scale clinical validation
Need for structured reader training
Lack of formal regulatory approval

Cite This Study

Panagiotidis et al. (2026) studied this question.

synapsesocial.com/papers/6a0ea13abe05d6e3efb5fbc3 https://doi.org/10.3390/diagnostics16101542

View Full Paper

Ask AI

Bookmark

Implication

FAPI PET may enhance fibrosis imaging in oncologic and fibroinflammatory diseases; leaves open prospective cardiovascular validation before clinical adoption.

Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider